Pharmacology · Cardiovascular

Hypertension in the Elderly & Isolated Systolic Hypertension

Arterial stiffness, frailty-adjusted targets, and age-specific pharmacology

Isolated systolic hypertension in older adults results from arterial stiffening — elastin is replaced by collagen, advanced glycation end products create cross-links, and endothelial dysfunction reduces nitric oxide — eliminating the Windkessel effect by which a healthy aorta absorbs stroke volume during systole and recoils during diastole; the result is a rising systolic and falling diastolic pressure, a widened pulse pressure, and coronary perfusion that becomes vulnerable if diastolic pressure drops below 65 to 70 mm Hg.
Four landmark trials established treatment benefit: SHEP demonstrated a 36 percent stroke reduction with chlorthalidone; Syst-Eur showed a 42 percent stroke reduction with nitrendipine; HYVET proved indapamide safe and beneficial even above age 80 with a 21 percent reduction in all-cause mortality; and the SPRINT elderly subgroup showed intensive control below 120 mm Hg systolic reduced cardiovascular events by 34 percent in non-frail patients aged 75 or older.
Drug selection in elderly ISH prioritizes the low-renin mechanism: thiazide-like diuretics (chlorthalidone, indapamide) and dihydropyridine calcium channel blockers (amlodipine preferred for its 35 to 50 hour half-life) are first-line; beta-blockers are ineffective for systolic reduction and cause fatigue, exercise intolerance, and falls; alpha-1 blockers carry high orthostatic hypotension risk and increased heart failure risk by ALLHAT evidence.
Frailty modifies the benefit-risk calculation: fit elderly patients (Clinical Frailty Scale 1 to 3) should be treated to below 130 mm Hg; pre-frail patients to below 140 mm Hg with slower titration; frail patients require individualization with active consideration of de-prescribing if falls or declining function appear; and in very frail or end-of-life patients, antihypertensive withdrawal should be actively considered.
Age-related pharmacokinetic changes demand dose adjustment throughout: GFR declines approximately 1 mL/min/year after age 40 causing renal-excreted drugs (atenolol, lisinopril) to accumulate; reduced hepatic first-pass raises bioavailability of labetalol and nifedipine; increased body fat prolongs half-lives of lipophilic drugs; and lipophilic drugs cross the blood-brain barrier more readily, increasing CNS sensitivity to clonidine, methyldopa, and lipophilic beta-blockers.

Abbreviations: ISH = isolated systolic hypertension · SBP = systolic blood pressure · DBP = diastolic blood pressure · AGE = advanced glycation end products · CCB = calcium channel blocker · DHP = dihydropyridine · RAAS = renin-angiotensin-aldosterone system · ACEi = angiotensin converting enzyme inhibitor · ARB = angiotensin receptor blocker · HFrEF = heart failure with reduced ejection fraction · AF = atrial fibrillation · BPH = benign prostatic hyperplasia · CAD = coronary artery disease · CFS = Clinical Frailty Scale · NSAIDs = nonsteroidal anti-inflammatory drugs · GFR = glomerular filtration rate · CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration · MI = myocardial infarction

Why Isolated Systolic Hypertension Develops in the Elderly

Loss of the Windkessel Effect

Arterial Stiffness → Isolated Systolic Hypertension

Normal aorta (Windkessel effect): expands during systole to absorb stroke volume → damped pressure wave; recoils during diastole to maintain diastolic pressure and coronary perfusion
Aging aorta (stiff): elastin fragments and replaced by collagen; AGE cross-linking; medial calcification; endothelial dysfunction reduces nitric oxide
Result — isolated systolic hypertension: SBP rises (no damping) + DBP falls (no elastic recoil) = widened pulse pressure
Pulse pressure above 60–70 mm Hg predicts high cardiovascular event rates
Systolic BP more powerful cardiovascular predictor than diastolic after age 50–55
J-curve caution: avoid reducing DBP below 65–70 mm Hg in patients with established coronary artery disease — coronary perfusion is diastole-dependent

Trial Evidence — Treatment Benefit Is Firmly Established

Low-Renin ISH Responds Best to Diuretics and CCBs

SHEP (1991): chlorthalidone in ISH (age ≥60) vs placebo → 36% reduction in stroke; 54% reduction in heart failure; established thiazide-like diuretics as cornerstone agents
Syst-Eur (1997): nitrendipine (DHP CCB) in ISH (age ≥60) vs placebo → 42% reduction in stroke; 31% reduction in cardiovascular events; established DHP CCBs as equally effective first-line agents
HYVET (2008): indapamide ± perindopril in age ≥80 vs placebo → 21% reduction in all-cause mortality; 64% reduction in heart failure; fewer serious adverse events than placebo — proven safe in very elderly
SPRINT elderly subgroup (2016): intensive target below 120 mm Hg (by automated unattended measurement ≈130 mm Hg standard) in age ≥75 → 34% reduction in cardiovascular events; 33% reduction in mortality in non-frail elderly

Drug Selection in Elderly Hypertension — Preferred vs Avoid

First-Line — Effective in Low-Renin ISH

Preferred Agents

Thiazide-like diuretics (chlorthalidone, indapamide): SHEP and HYVET evidence; most effective in volume-dependent ISH; chlorthalidone 12.5–25 mg or indapamide 1.25–2.5 mg; monitor sodium (hyponatremia risk especially in elderly women), potassium, creatinine; check orthostatic BP every visit
DHP CCBs (amlodipine): Syst-Eur evidence; renin-independent mechanism — effective in low-renin ISH; amlodipine preferred (half-life 35–50 hours, smooth 24-hour control, buffer for missed doses); no electrolyte or renal effects; peripheral edema managed by adding RAAS inhibitor
ACEi or ARB (with compelling indication): less effective as monotherapy in low-renin ISH; effective add-on to diuretic or CCB; ARB preferred over ACEi (avoid cough in elderly); perindopril added to indapamide in HYVET; monitor creatinine and potassium closely
Cognitively neutral and orthostatic-safe: amlodipine, chlorthalidone, ARBs — preferred when cognitive effects or falls are concerns

Use with Caution or Avoid in Elderly ISH

Problematic Agents

Beta-blockers: not first-line for isolated systolic hypertension; less effective for systolic reduction; fatigue, exercise intolerance, falls, depression, cold extremities; reserve for compelling indications (HFrEF, post-MI, AF rate control); prefer bisoprolol or nebivolol; avoid atenolol (renal accumulation, LIFE trial inferior outcomes)
Alpha-1 blockers (doxazosin, terazosin): high orthostatic hypotension and first-dose syncope risk → falls and hip fractures; ALLHAT: increased heart failure as monotherapy; useful only as add-on for concurrent BPH — lowest dose at bedtime
Centrally acting agents (clonidine, methyldopa): sedation, cognitive impairment, depression, falls — generally avoided in the elderly; use only when all other options have failed
Short-acting DHP CCBs (immediate-release nifedipine): contraindicated for hypertension management in elderly — exaggerated reflex tachycardia and BP variability, harmful in concurrent CAD

Frailty-Adjusted Targets & Start-Low-Go-Slow Dosing

Frailty Modifies the Benefit-Risk Calculation — Individualize Aggressively

Targets and Approach by Frailty Status

Frailty Status (Clinical Frailty Scale)	Systolic Target	Clinical Approach
Fit (CFS 1–3)	Below 130 mm Hg	Treat to evidence-based targets; SPRINT-level targets reasonable in non-frail elderly aged 75 or above; standard monitoring
Pre-frail (CFS 4–5)	Below 140 mm Hg	Standard targets with careful monitoring; check orthostatic BP every visit; titrate every 4–6 weeks rather than 2–4 weeks
Frail (CFS 6–8)	Individualized — quality of life priority	De-prescribing should be actively considered if adverse effects (falls, orthostatic hypotension, declining function) are present; benefit-risk shifts unfavorably with advancing frailty
Very frail / End of life (CFS 8–9)	Withdraw if not tolerated	Antihypertensive withdrawal should be actively considered; comfort and quality of life take priority over blood pressure targets

Start-Low-Go-Slow — Standard Starting Doses in Elderly Patients

Begin at half the standard adult starting dose: Chlorthalidone 6.25 mg (standard 12.5 mg) • Amlodipine 2.5 mg (standard 5 mg) • Perindopril 2 mg (standard 4 mg) • Losartan 25 mg (standard 50 mg) • Lisinopril 2.5 mg (standard 5 mg). Titrate every 4–6 weeks (not 2–4). Review the complete medication list at every visit — average elderly hypertensive patient takes 5–7 prescriptions; NSAIDs blunt diuretics and RAAS inhibitors and must be identified every review.

Orthostatic Hypotension & Age-Related Pharmacokinetic Changes

Prevalence 20% Community / 50% Institutionalized

Orthostatic Hypotension

Definition: SBP fall ≥20 mm Hg or DBP fall ≥10 mm Hg within 3 minutes of standing
Associated with approximately 2× risk of falls, syncope, and cardiovascular events
Most problematic agents: alpha-1 blockers, loop diuretics, CCBs
Check BP sitting AND standing at every visit in elderly hypertensive patients
Management: simplify regimen; avoid diuretics in evening; adequate hydration; compression stockings; slow positional changes; avoid alcohol

GFR Declines ~1 mL/min/Year After Age 40

Pharmacokinetic Changes with Aging

Use CKD-EPI equation (not serum creatinine alone) — reduced muscle mass causes creatinine to underestimate renal impairment
Renally excreted drugs accumulate: atenolol, lisinopril (dose reduction required)
Reduced hepatic first-pass: higher bioavailability of labetalol, metoprolol, nifedipine, amlodipine
Increased body fat relative to lean mass: lipophilic drugs have larger volume of distribution and longer half-lives
Lipophilic drugs cross blood-brain barrier more readily: increased CNS sensitivity to clonidine, methyldopa, lipophilic beta-blockers
Polypharmacy risk: 5–7 concurrent medications average; NSAIDs are the most common BP-raising interactant

Suggested References

Author / Organization	Title	Source
Katzung BG, ed.	Basic and Clinical Pharmacology. 15th ed.	McGraw-Hill; 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.	McGraw-Hill; 2023
Whelton PK, Carey RM, Aronow WS, et al.	2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults	J Am Coll Cardiol. 2018;71(19):e127–e248
Mancia G, Kreutz R, Brunstrom M, et al.	2023 ESH guidelines for the management of arterial hypertension	J Hypertens. 2023;41(12):1874–2071
SHEP Cooperative Research Group	Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension (SHEP)	JAMA. 1991;265(24):3255–3264
Staessen JA, Fagard R, Thijs L, et al.	Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension (Syst-Eur)	Lancet. 1997;350(9080):757–764
Beckett NS, Peters R, Fletcher AE, et al.	Treatment of hypertension in patients 80 years of age or older (HYVET)	N Engl J Med. 2008;358(18):1887–1898
SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, et al.	A randomized trial of intensive versus standard blood-pressure control (SPRINT)	N Engl J Med. 2015;373(22):2103–2116
Fried LP, Tangen CM, Walston J, et al.	Frailty in older adults: evidence for a phenotype	J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–M156
Dahlof B, Devereux RB, Kjeldsen SE, et al.	Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE)	Lancet. 2002;359(9311):995–1003
Williamson JD, Supiano MA, Applegate WB, et al.	Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged 75 years or older (SPRINT elderly subgroup)	JAMA. 2016;315(24):2673–2682
Gangavati A, Hajjar I, Quach L, et al.	Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population	J Am Geriatr Soc. 2011;59(3):383–389
ALLHAT Officers and Coordinators	Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT)	JAMA. 2002;288(23):2981–2997
Aronow WS, Fleg JL, Pepine CJ, et al.	ACCF/AHA 2011 expert consensus document on hypertension in the elderly	J Am Coll Cardiol. 2011;57(20):2037–2114